Key result
This review discusses the interactions between prostaglandins and cardiovascular physiology, addressing concerns regarding COX-2-specific drugs and the risk of cardiovascular events.
Comparison
COX-2-specific drugs vs Traditional nonsteroidal antiinflammatory drugs
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Urges caution with COX-2 inhibitors in patients at cardiovascular risk; leaves open precise mechanistic quantification in prospective studies.
Structured PICO
I
Intervention
COX-2-specific drugs (rofecoxib, celecoxib, etoricoxib, valdecoxib)
C
Comparator
Traditional nonsteroidal antiinflammatory drugs (tNSAIDs)
This review highlights the complex interactions between COX-derived prostaglandins and cardiovascular physiology, addressing safety concerns regarding cardiovascular events with COX-2 inhibitors.
Cite This Study
Garret A. FitzGerald (2004) conducted a review in Cardiovascular risk with COX-2 inhibitors. COX-2-specific drugs (coxibs) vs. Traditional NSAIDs was evaluated. This review discusses the interactions between prostaglandins and cardiovascular physiology, addressing concerns regarding COX-2-specific drugs and the risk of cardiovascular events.